Company: OSRH
Filing Date: 2025-06-10
Form Type: S-1/A
Source: 0001213900-25-053114
Chunk: 21

Company: OSR Holdings, Inc.
Filing Date: 2025-06-10
Form: S-1/A
Chunk 21
---
 statement), but there is no guaranty     
 that these arrangements will be fully consummated and/or sufficient and that the Company may not face claims from creditors (some of 
 which have already been initiated – see “Litigation” below) that could cause voluntary or involuntary                                
 bankruptcy proceedings, in which case, the value of the stock and warrants of the Company would likely be worthless.                 |

| ● | The price of the Company’s Common Stock and warrants may be volatile. If you purchase common                                      
 stock in this offering, you will suffer immediate dilution of your investment.                                                    |
| ● | The Company is a controlled company within the meaning of the Nasdaq Listing Rules and, as a result,                              
 will qualify for, and may rely on, exemptions from certain corporate governance requirements. Stockholders of the Company may not 
 have the same protection afforded to stockholders of companies that are subject to such governance requirements.                  |

| ● | An active, liquid trading market for the Company Common Stock and warrants may not develop or persist, 
 which may limit your ability to sell the Company Common Stock and warrants.                            |

| ● | The Company’s limited operating history, the early stage of its development programs and the                                         
 inherent uncertainties and risks involved in pharmaceutical and medical product development may make it difficult for it to execute  
 on its business model. Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance     
 to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a     
 timely basis or at all. the regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming  
 and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business 
 will be materially harmed                                                                                                            |

| ● | The Company will likely incur significant operating losses for the foreseeable future and may never 
 achieve or maintain profitability.                                                                  |

| ● | We may not be successful in our efforts to acquire, in-license or discover and develop new product 
 candidates.                                                                                        |

| ● | We currently have no marketing and sales organization for pharmaceutical products and have no experience                               
 as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are     
 unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our pharmaceutical 
 products, we may not be able to generate pharmaceutical product revenue.                                                               |

12

| ● | Our investment strategy and future growth relies on